FDA inspection outcomes: selected CEE/MENA countries
When evaluating countries for clinical trials, sponsors typically focus on factors such as patient recruitment potential, timelines, and costs. However, there is another critical indicator that is crucially important – quality. There are different ways to measure this important metrics, however one of the most objective ones is regulatory inspection performance.
FDA inspection outcomes offer valuable insight into the quality of clinical trial execution, site oversight, documentation practices, and overall compliance with international standards. They provide a real-world measure of how well research sites and study teams perform under regulatory assessment.
Looking at selected countries across CEE and MENA, the data highlights a strong track record of inspection readiness and quality performance.
No Action Indicated (NAI) findings – which is most favorable outcome of FDA inspection and the only one when no FDA 483 is being issued: • Georgia: 100.0% • Ukraine: 79.4% • Poland: 70.5% • Israel: 48.2%
For comparison: • US: 64% • Western Europe: 41,6% • Nordics: 42,2%
These results underscore the maturity of clinical research ecosystems across the CEE and MENA regions and demonstrate the ability of investigators, sites, and study teams to consistently meet global regulatory and quality expectations.
As sponsors continue to seek efficient, high-performing regions for clinical development, CEE and MENA stand out not only for recruitment capabilities but also for their strong quality culture and inspection readiness.
At PVR (People. Value. Research), we work closely with experienced investigators and research sites across these regions, helping sponsors achieve both operational efficiency and high-quality study delivery.
In clinical research, speed matters, but quality is what sustains success.
.png)
.svg)
.svg)
.svg)
